137 related articles for article (PubMed ID: 10897765)
1. [In vitro oxygen-dependent survival of 2 human cell lines after radiation combined with tirapazamine (SR-4233) and cisplatin].
Lartigau E; Stern S; Guichard M
Cancer Radiother; 2000; 4(3):217-22. PubMed ID: 10897765
[TBL] [Abstract][Full Text] [Related]
2. Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure?
Lartigau E; Guichard M
Int J Radiat Biol; 1995 Feb; 67(2):211-6. PubMed ID: 7884290
[TBL] [Abstract][Full Text] [Related]
3. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
Lartigau E; Guichard M
Br J Cancer; 1996 Jun; 73(12):1480-5. PubMed ID: 8664116
[TBL] [Abstract][Full Text] [Related]
4. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
Zhang M; Stevens G
Melanoma Res; 1998 Dec; 8(6):510-5. PubMed ID: 9918413
[TBL] [Abstract][Full Text] [Related]
5. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.
Goldberg Z; Evans J; Birrell G; Brown JM
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):175-82. PubMed ID: 11163512
[TBL] [Abstract][Full Text] [Related]
6. The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity.
Lambin P; Guichard M; Chavaudra N; Malaise EP
Radiother Oncol; 1992 Jul; 24(3):201-4. PubMed ID: 1410575
[TBL] [Abstract][Full Text] [Related]
7. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Takahashi M; Abe M
Br J Cancer Suppl; 1996 Jul; 27():S61-4. PubMed ID: 8763848
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
Patterson AV; Saunders MP; Chinje EC; Talbot DC; Harris AL; Strafford IJ
Br J Cancer; 1997; 76(10):1338-47. PubMed ID: 9374381
[TBL] [Abstract][Full Text] [Related]
9. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
Zeman EM; Brown JM; Lemmon MJ; Hirst VK; Lee WW
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1239-42. PubMed ID: 3744945
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of combined treatment with mild temperature hyperthermia and/or tirapazamine in the treatment of solid tumors: its independence of p53 status.
Masunaga S; Ono K; Takahashi A; Ohnishi K; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Nagasawa H; Uto Y; Hori H
Cancer Sci; 2003 Jan; 94(1):125-33. PubMed ID: 12708486
[TBL] [Abstract][Full Text] [Related]
11. Pre- and post-irradiation radiosensitization by SR 4233.
Zeman EM; Brown JM
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):967-71. PubMed ID: 2703404
[TBL] [Abstract][Full Text] [Related]
12. Tirapazamine: from bench to clinical trials.
Marcu L; Olver I
Curr Clin Pharmacol; 2006 Jan; 1(1):71-9. PubMed ID: 18666379
[TBL] [Abstract][Full Text] [Related]
13. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors.
Hicks KO; Siim BG; Pruijn FB; Wilson WR
Radiat Res; 2004 Jun; 161(6):656-66. PubMed ID: 15161354
[TBL] [Abstract][Full Text] [Related]
14. Aerobic radiosensitization by SR 4233 in rodent and human cells: mechanistic and therapeutic implications.
Zeman EM; Brown JM
Int J Radiat Biol; 1991 Jan; 59(1):117-31. PubMed ID: 1671059
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
Dorie MJ; Menke D; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.
Zeman EM; Hirst VK; Lemmon MJ; Brown JM
Radiother Oncol; 1988 Jul; 12(3):209-18. PubMed ID: 3175048
[TBL] [Abstract][Full Text] [Related]
17. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
Brown JM
Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
[TBL] [Abstract][Full Text] [Related]
18. The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).
Patterson AV; Robertson N; Houlbrook S; Stephens MA; Adams GE; Harris AL; Stratford IJ; Carmichael J
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):369-72. PubMed ID: 8195035
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of agents counteracting hypoxia in fractionated radiation regimes.
Stern S; Guichard M
Radiother Oncol; 1996 Nov; 41(2):143-9. PubMed ID: 9004358
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of tirapazamine as a combined agent in chemoradiation and thermo-chemoradiation therapy at mild temperatures: reference to the effect on intratumor quiescent cells.
Masunaga SI; Ono K; Suzuki M; Kinashi Y; Takagaki M; Hori H; Kasai S; Nagasawa H; Uto Y
Jpn J Cancer Res; 2000 May; 91(5):566-72. PubMed ID: 10835503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
